ABCM - Abcam plc
Close
23.99
0.010 0.042%
Share volume: 0
Last Updated: Tue 05 Dec 2023 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$23.98
0.01
0.04%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-4.22%
1 Month
-8.03%
3 Months
28.95%
6 Months
43.36%
1 Year
49.77%
2 Year
10.05%
Key data
Stock price
$23.99
DAY RANGE
N/A - N/A
52 WEEK RANGE
$12.48 - $25.32
52 WEEK CHANGE
$0.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Alan T. Hirzel
Region: US
Website: abcam.com
Employees: 1,750
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abcam.com
Employees: 1,750
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Abcam plc focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of Asia Pacific.
Recent news